SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity

0563741 - MBÚ 2023 RIV CH eng J - Článek v odborném periodiku
Antošová, Z. - Podzimkova, N. - Tomala, Jakub - Augustýnková, K. - Sajnerová, K. - Nedvědová, E. - Šírová, Milada - de Martynoff, G. - Bechard, D. - Moebius, U. - Kovář, Marek - Špíšek, R. - Adkins, I.
SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity.
Frontiers in Immunology. Roč. 13, OCT 10 2022 (2022), č. článku 989895. ISSN 1664-3224. E-ISSN 1664-3224
Institucionální podpora: RVO:61388971
Klíčová slova: NK cells * antibody-dependent cytotoxicity * interleukin-15 * immunotherapy * therapeutic antibodies * rli-15
Obor OECD: Oncology
Impakt faktor: 7.3, rok: 2022
Způsob publikování: Open access
https://www.frontiersin.org/articles/10.3389/fimmu.2022.989895/full

SOT101 is a superagonist fusion protein of interleukin (IL)-15 and the IL-15 receptor alpha (IL-15R alpha) sushi+ domain, representing a promising clinical candidate for the treatment of cancer. SOT101 among other immune cells specifically stimulates natural killer (NK) cells and memory CD8(+) T cells with no significant expansion or activation of the regulatory T cell compartment. In this study, we showed that SOT101 induced expression of cytotoxic receptors NKp30, DNAM-1 and NKG2D on human NK cells. SOT101 stimulated dose-dependent proliferation and the relative expansion of both major subsets of human NK cells, CD56(bright)CD16(-) and CD56(dim)CD16(+), and these displayed an enhanced cytotoxicity in vitro. Using human PBMCs and isolated NK cells, we showed that SOT101 added concomitantly or used for immune cell pre-stimulation potentiated clinically approved monoclonal antibodies Cetuximab, Daratumumab and Obinutuzumab in killing of tumor cells in vitro. The anti-tumor efficacy of SOT101 in combination with Daratumumab was assessed in a solid multiple myeloma xenograft in CB17 SCID mouse model testing several combination schedules of administration in the early and late therapeutic setting of established tumors in vivo. SOT101 and Daratumumab monotherapies decreased with various efficacy tumor growth in vivo in dependence on the advancement of the tumor development. The combination of both drugs showed the strongest anti-tumor efficacy. Specifically, the sequencing of both drugs did not matter in the early therapeutic setting where a complete tumor regression was observed in all animals. In the late therapeutic treatment of established tumors Daratumumab followed by SOT101 administration or a concomitant administration of both drugs showed a significant anti-tumor efficacy over the respective monotherapies. These results suggest that SOT101 might significantly augment the anti-tumor activity of therapeutic antibodies by increasing NK cell-mediated activity in patients. These results support the evaluation of SOT101 in combination with Daratumumab in clinical studies and present a rationale for an optimal clinical dosing schedule selection.
Trvalý link: https://hdl.handle.net/11104/0335572